Keele Research Repository

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Osteoarthritis (OA) has a major impact on the global burden of disease and is associated with poorer cardiovascular disease (CVD) outcomes. However it’s unclear whether people with OA have higher long-term (10-year) CVD risk compared to people without OA. This study uses electronic health record (EHR) data from a national representative database to calculate the Framingham-score (a gender-specific risk algorithm) to test the hypothesis that OA consulters have higher long-term CVD risk than non-OA consulters.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>205,368 incident OA consulters with 1:1 age, gender, and practice-matched non-OA controls extracted from Clinical Practice Research Datalink (CPRD) were included. All predictors extracted from EHRs within three years prior to the index consultation were used to fit the Framingham-score. Absolute difference (AR) and relative rate ratio (RR) in the proportion of high-risk (predicted-risk ≥20%) individuals between OA and controls were estimated using Poisson regression.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The proportion of high-risk individuals was higher in consulters for OA (5.69 (95% confidence interval (CI): 5.59-5.79)%) cf. 4.37 (4.28-4.46)%). The adjusted AR and RR was (1.94 (95%CI: 1.78-2.10) %) and (1.30 (1.27-1.34)), respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study confirms the expected higher predicted 10-year CVD risk in OA consulters compared to controls. This suggests that OA consulters could be a target group for more proactive interventions to prevent CVD events.</jats:p> </jats:sec> <jats:sec> <jats:title>Key messages</jats:title> <jats:p>OA consulters have a higher CVD risk predicted by Framingham-score calculated using EHRs than controls; OA consulters are a high risk group that can be considered as a target group for proactive prevention interventions for CVD.</jats:p> </jats:sec>